Skip to main content
17, Oct 2020
WHO Solidarity Trial of Repurposed Antiviral Drugs in COVID-19 Reports Little to No Effect

WHO Solidarity Trial of Repurposed Antiviral Drugs in COVID-19 Reports Little to No Effect on Mortality, Seve

Read more
15, Nov 2016
Predicting Cytomegalovirus Viremia… With CMV-Specific T-cells

Predicting cytomegalovirus viremia after liver or intestine transplantation (LTx, ITx) with CMV-specific T-cell subse

Read more
15, Nov 2016
Predicting Cellular Rejection With a Cell-Based Assay: Preclinical Evaluation in Children

Allospecific CD154+T-cytotoxic memory cells (CD154+TcM) predict acute cellular rejection after liver transplantation

Read more
Subscribe to News

About

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.

Contact